Indivior Pharmaceuticals, Inc. Common Stock Earnings Dividend

Indivior Pharmaceuticals, Inc. Common Stock’s revenue jumped 13.58% since last year same period to $343Mn in the Q2 2026. On a quarterly growth basis, Indivior Pharmaceuticals, Inc. Common Stock has generated 8.2% jump in its revenue since last 3-months.

Indivior Pharmaceuticals, Inc. Common Stock’s net profit jumped 577.78% since last year same period to $122Mn in the Q2 2026. On a quarterly growth basis, Indivior Pharmaceuticals, Inc. Common Stock has generated 37.08% jump in its net profits since last 3-months.

Indivior Pharmaceuticals, Inc. Common Stock’s net profit margin jumped 496.76% since last year same period to 35.57% in the Q2 2026. On a quarterly growth basis, Indivior Pharmaceuticals, Inc. Common Stock has generated 26.69% jump in its net profit margins since last 3-months.

Indivior Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at 0.97 - a 46.97% jump from last quarter’s estimates.

Indivior Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at 0.97.

Indivior Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) jumped 125.49% since last year same period to 1.15 in the Q2 2026. This indicates that the Indivior Pharmaceuticals, Inc. Common Stock has generated 125.49% annual rate of jump in its earning per share (EPS) in the last 4 quarters.